A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Janssen Research & Development, LLC
- Study ID
- NCT07309445
- Status
- Recruiting
Conditions
- Non-Muscle Invasive Bladder Neoplasms
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
The purpose of this study is to assess how well TAR-200 works in real-word by measuring the time taken from the first TAR-200 insertion to worsening of cancer or until the signs and symptoms of cancer occur again (disease-free survival) in participants with non-muscle invasive bladder cancer (NMIBC; an early-stage bladder cancer that is limited to the inner lining of bladder).
Key Dates
- First listed
- Dec 30, 2025
- Start date
- Jun 12, 2026
- Status verified
- Jul 2026
- Primary completion
- Mar 31, 2029
- Completion
- Oct 9, 2029
Study Design
- Enrollment
- 150 participants (estimated)
Arms
- Arm: NMIBC Participants: Routine Clinical Practice SettingParticipants with confirmed diagnosis of NMIBC and who have initiated first dose of TAR-200 in a real-world clinical setting, within 6 weeks prior to baseline visit/Study visit 1 will be observed for 24 months from the initiation of the first dose of TAR-200, or until the participant dies, is lost to follow-up, or withdraws consent in the study. No intervention will be administered as a part of this study.
Primary Outcome Measure
Disease-Free Survival (DFS) [ Time Frame: Up to 24 months ]
Central Contacts
- Study Contact844-434-4210
- Eliza M. Raymundo, MD, DMCC, FPUA, FPCS1-669-800-7705
Locations (13)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | - |
| Arkansas Urology | Little Rock | Arkansas | 72211 | - |
| Cedars Sinai Medical Center | Los Angeles | California | 90048 | - |
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | - |
| Colorado Clinical Research | Lakewood | Colorado | 80228 | - |
| Florida Urology Partners | Wimauma | Florida | 33598 | - |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | - |
| Specialty Clinical Research of St Louis | St Louis | Missouri | 63141 | - |
| SUNY Upstate Med Univ | Syracuse | New York | 13210 | - |
| Urology Specialists of the Carolinas PLLC Charlotte | Charlotte | North Carolina | 28204 | - |
| Urology Specialists of South Dakota | Sioux Falls | South Dakota | 57108 | - |
| UPNT Research Institute | Arlington | Texas | 76017 | - |
| Spokane Urology | Spokane | Washington | 99202 | - |
Find similar trials in Birmingham, AL
Related Studies
- Study of Erdafitinib Intravesical Delivery System for Localized Bladder CancerPHASE1/PHASE2 · Recruiting · Janssen Research & Development, LLC · Birmingham, Alabama
- A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder CancerPHASE1 · Recruiting · Aura Biosciences · Los Angeles, California
- A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder CancerPHASE3 · Recruiting · Janssen Research & Development, LLC · Little Rock, Arkansas
- A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Bakersfield, California